Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Sub-group analysis from Blue Earth Diagnostics’ Phase 3 LIGHTHOUSE trial highlights POSLUMA utility to guide treatment selection and potentially avoid futile surgery

Related Keywords

Germany ,Munich ,Bayern ,Davide Gauden ,Garya Ulaner ,Scintomics Gmb ,Philliph Kuo ,Los Angeles ,University Of Arizona ,Study Group ,Drug Administration ,University Of Southern California ,Solutions Inc ,Hoag Family Cancer Institute ,Technical University Of Munich ,A Siemens Healthineers Company ,Blue Earth Diagnostics ,True Positive ,Detection Rate ,Medical Imaging ,Chief Executive Officer ,Blue Earth ,Siemens Healthineers ,Newly Diagnosed High Risk Prostate Cancer ,Negative Conventional Imaging ,Biomedical Engineering ,Southern California ,Radiohybrid Prostate Specific Membrane Antigen ,Prostate Specific Membrane Antigen ,Prostate Specific Membrane Antigen Targeted ,Technical University ,Scintomics Gmbh ,Important Safety Information About ,Image Misinterpretation ,Suspected Prostate Cancer Recurrence ,